Leading With Compassion: Manipal Hospitals Launches Inspiring Biography and Leadership Journey of Dr. H. Sudarshan Ballal
BENGALURU, India , May 27, 2025 /PRNewswire/ — Manipal Hospitals today announced the launch of 'Leading With Compassion', a compelling biography of Dr. H. Sudarshan Ballal , Chairman- Manipal Hospitals. Authored by Mr. Stephen David , this book offers an intimate yet universally relevant exploration of leadership through Dr. Ballal's five-decade journey. More than a traditional biography, this book serves as a vital resource for aspiring medical professionals and leaders globally, distilling the principles and values that have shaped Dr. Ballal's extraordinary career in healthcare. The book was unveiled by the Hon'ble Chief Minister of Karnataka, Shri Siddaramaiah .
'Leading With Compassion' meticulously traces Dr. Ballal's early life experiences, revealing the foundations of his character and dedication. The book then navigates through his pivotal professional milestones, highlighting the key decisions and challenges that shaped his illustrious career in medicine and leadership. It provides invaluable insights, equipping readers with the wisdom to navigate the intricate and ever-evolving complexities of the medical landscape, both within India and on the global stage. The Foreword for this significant work has been penned by Padma Vibhushan awardee Justice M. N. Venkatachaliah, former Chief Justice of India , who was also present at the event.
Dr. H. Sudarshan Ballal is a titan in Indian nephrology, renowned for being among the first in the U.S. to achieve triple board certification in Internal Medicine, Nephrology, and Critical Care. His return to India in the early 1990s marked a pivotal moment for Indian healthcare, as he spearheaded the establishment of Manipal's pioneering nephrology program. Under his visionary leadership, Karnataka witnessed its first cadaver kidney transplant and the inception of its first DNB nephrology program. Dr. Ballal's profound contributions have been recognized with numerous accolades, including the prestigious Rajyotsava Award, Dr. B.C. Roy Award, and the Times Lifetime Achievement Award.
The book launch was graced by an esteemed gathering of dignitaries, including Justice M. N. Venkatachaliah , Padma Vibhushan awardee and former Chief Justice of India ; Shri N. Santosh Hegde , former Supreme Court Judge and former Lokayukta of Karnataka; Mr. Dinesh Gundu Rao , Minister for Health and Family Welfare, Government of Karnataka; Dr. Ranjan R. Pai , Chairman of Manipal Education and Medical Group; Dr. C. N. Manjunath, Padma Shri awardee, renowned cardiologist, and Member of Parliament (Lok Sabha); Dr. H. S. Ballal, Pro Chancellor of Manipal Academy of Higher Education; Mr. Dilip Jose , Managing Director and CEO of Manipal Health Enterprises Pvt. Ltd.; Dr. K. Govindaraj, MLC and Political Secretary to the Chief Minister of Karnataka; and Ms. Sapthami Gowda, acclaimed Indian actress.
Dr. H. Sudarshan Ballal , Chairman, Manipal Hospitals, stated, 'Leadership in medicine is not just about titles or technology—it's about touching lives with empathy, staying true to your values, and leading by example. I have always believed that compassion is as essential as competence. If this book can inspire even a few young doctors to serve with heart and purpose, then it will have served its goal.'
Beyond his clinical and administrative prowess, Dr. Ballal is deeply committed to ensuring equitable healthcare access. His leadership has driven numerous impactful Corporate Social Responsibility (CSR) initiatives, such as providing free pediatric kidney transplants and establishing vital rural health programs. 'Leading With Compassion' encapsulates this spirit, offering readers a unique perspective on leadership grounded in empathy and ethical practice.
This book is poised to become an indispensable guide for young doctors and professionals seeking to make a meaningful impact in the healthcare sector.
For more information, please visit: https://www.manipalhospitals.com/
Photo: https://mma.prnewswire.com/media/2696638/Book_Launch_Manipal_Hospitals.jpg
Photo: https://mma.prnewswire.com/media/2696639/Book_Unveiling_Manipal_Hospitals.jpg
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Illuminating ctDNA-MRD: Gene Solutions' K-CONNECT APAC 2025 Sparks Regional Collaboration in Precision Oncology
DA NANG, Vietnam, May 31, 2025 /PRNewswire/ -- May 9-11, 2025, Gene Solutions, a pioneer in AI-driven precision oncology hosted K-CONNECT APAC 2025, a pivotal summit uniting over 100 distinguished oncologists and molecular biologists from nine Asia-Pacific countries. — This landmark event marked a significant milestone in advancing precision oncology, fostering collaboration, and driving innovation in the fields of circulating tumor DNA (ctDNA), Molecular Residual Disease (MRD), and Comprehensive Genomic Profiling (CGP). Under the theme "Empowering the Potential of ctDNA-MRD," 16 distinguished speakers and panelists shared clinical insights, breakthrough research, and innovative strategies for integrating ctDNA-MRD into cancer practice. "While ctDNA and MRD are invisible to the eye, K-CONNECT APAC 2025 shed transformative light on their potential through regional collaboration and clinical innovation," said Ida Deleskog Lindstrom, Global Medical Affairs Director at Gene Solutions. "Illuminating ctDNA-MRD means revealing actionable insights that spark hope, clarity, and progress through molecular insights to transform precision oncology." "K-CONNECT APAC 2025 was a transformative moment for precision oncology in the Asia-Pacific, bringing together diverse expertise to translate ctDNA-MRD advancements into real-world clinical impact'' said Professor Nick Pavlakis, Co-Chair of the summit and a leading medical oncologist from Australia. "This summit has set a new benchmark for collaborative innovation, paving the way for personalized cancer care across the region'' A First-of-Its-Kind Gathering in Asia-Pacific Gene Solutions, a regional pioneer in ctDNA-MRD testing, has supported over 6,000 cancer patients via its next generation comprehensive AI-powered K-TRACK® and K-4CARE® platforms. K-CONNECT APAC 2025 showcased its role in fostering cross-border expertise to accelerate adoption of precision diagnostics. The summit featured three key sessions shared by 16 esteemed experts K-CONNECT ACADEMIC Session: The Importance of ctDNA-MRD and CGP in Precision Oncology Unique Combination of Genomic & Transcriptomic Profiling with ctDNA-MRD Monitoring Key findings from Asia's First Real-World Study of ctDNA-MRD Monitoring in Solid Tumors. K-CONNECT CASE SHARING Session ctDNA-MRD Applications & Real-World Case Sharing in Colorectal, Lung and Breast cancers. K-CONNECT NEXT LANDMARK Session Genetic Testing Guided Personalized Immunotherapy in Refractory Solid Tumors. Triad of Impact– A Multi-omic Solution to Advance Precision Oncology Innovation. Beyond an Event — Establishing a Platform for Ongoing Impact K-CONNECT is evolving into a regional hub for knowledge exchange, clinical collaborations, and precision oncology innovation acceleration. Upcoming initiatives include: K-CONNECT Webinar Series – Ongoing expert-led case discussions Clinical Trials Collaboration – Cross-border partnerships with biopharma and research institutions Experience ctDNA-MRD Program – Hands-on implementation support for clinicians Knowledge Hub – A digital platform for APAC oncology insights Shaping the Future of Cancer Care K-CONNECT APAC 2025 solidified Gene Solutions' leadership in genetic testing and its commitment to advancing equitable access to innovative solutions to improve patient outcomes. By fostering collaboration and showcasing real-world impact, the summit laid the foundation for a more connected, data-driven, and patient-centered future in cancer care across the Asia-Pacific. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific. Explore more information at: MEDIA CONTACT: pr@ View original content to download multimedia: SOURCE Gene Solutions Genomics Pte Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 hours ago
- Yahoo
Global tobacco experts issue stark warning that the world is on brink of turning into an 'ashtray planet' that will significantly escalate chronic respiratory diseases
Twenty leading tobacco-control experts contributed to first-of-its-kind report visualising possible 2040 futures around nicotine consumption impact on diseases like asthma and COPD Report warns world could steer towards doomsday 'ashtray planet' scenario shrouded in second-hand smoke smog, with healthcare systems stretched to limits It calls for immediate action from health decision makers to persevere with generational bans, restrict nicotine to prescription only, and ban vape flavours or attractive packaging COPENHAGEN, Denmark, May 30, 2025 /PRNewswire/ -- The Copenhagen Institute for Futures Studies (CIFS), an independent non-profit think tank, gathered twenty tobacco-control specialists from Africa, Europe, the Middle East, North America, South America, and Southeast Asia, to explore four plausible futures to 2040 around nicotine use and the impact this will have on chronic respiratory diseases. Findings from the experts have been published in a first-of-its-kind report to analyse how tobacco and nicotine use could intersect chronic respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma. The report highlights four possible scenarios for 2040 depending on actions government, health decision makers and individuals take now around nicotine use. The experts were gathered to explore potential future scenarios and to highlight a course toward one 'endgame generation' scenario we must strive to significantly reduce nicotine use and improve chronic respiratory disease outcomes. At the same time, they also identified tipping points, which closely reflect the current geopolitical climate that risk steering the world to the worst-case scenario the experts deemed 'ashtray planet' by 2040. In the 'ashtray planet' scenario, tobacco and nicotine use has become deeply entrenched across much of the world. Second-hand smoke and aerosol are common in public spaces with people smoking on public transport, outside hospitals, or even in parks where children play. People begin wearing masks again, not for viruses, but to cope with outdoor smoke and smog. COPD and asthma become significantly more prevalent stretching health systems to the limit, not to mention the mental health burden on both patients and their caregivers. Health care professionals do little more than renew basic prescriptions, driving a revolving door of readmissions. A surge in undiagnosed asthma leads to attacks with often fatal consequences that could have been prevented among children, disproportionately affecting those in low and middle-income countries. Aron Szpisjak, Head of Health and Futurist at CIFS said: "Chronic respiratory diseases like asthma and COPD affect 550 million adults yet they are almost invisible in global health discussions. Tobacco is the leading preventable risk factor for these conditions, contributing to 8.3 million deaths every year." "With the risk of governments catering to corporate interests and economic survival dominating national agendas, what we saw as the doomsday scenario now feels dangerously close to being realised. We still have time to shape the future and steer us on the right course to an endgame where nicotine consumption is reduced significantly, and chronic respiratory diseases begin to decline. We already have the solutions to get us there and avert the ashtray planet scenario. But that can only happen if decision makers across the world commit to sustained, coordinated action." The report describes early warning signals, policy shifts and trends which could indicate the 'ashtray planet' scenario is beginning to unfold and underscores the urgency for action. For example, when more immediate crises such as economic instability, authoritarian politics, worsening environmental disasters, and mounting inequality lead governments to prioritise economic survival over public health resulting in rollbacks of tobacco-control regulations. Another example is the rise of newer nicotine products such as e-cigarettes, which rapidly gain popularity through social media and celebrity influence, particularly among young people. Chronic respiratory diseases impose a significant burden, particularly in low- and middle-income countries, where 90% of premature deaths occur due to underdiagnosis and limited access to care. In the scenario most closely resembling a status quo where developed countries do enact strong tobacco-control policies and uptake of new nicotine products is limited, the report highlights that positive outcomes may remain uneven. This is particularly the case in underserved regions where public trust in government and health institutions is low and there are varying abilities to adapt policies to local realities. Bogi Eliasen, CIFS Fellow and Futurist , said: "High smoking rates jeopardise our progress towards the Sustainable Development Goal of aiming to reduce premature mortality from non-communicable diseases. While smoking rates are dropping, progress is slow and insufficient. Delaying action further risks slowing progress, making tobacco use harder to reverse, and missing a critical opportunity to protect millions of people." "We have seen positive signs with the recent approval of the Integrated Lung Health resolution at the World Health Assembly, but there is still work to be done to ensure chronic respiratory diseases maintain priority status. As world leaders gather at the United Nations General Assembly in September this year to adopt a new declaration on non-communicable diseases later this year, they must take strong action on tobacco control and ensure people living with chronic respiratory diseases are meaningfully included in the commitments." The report includes strategic actions for policy makers, public health bodies, and patient and advocacy groups. Immediate priorities include strengthening tobacco control by persevering with action such as generational bans, restricting new nicotine products to prescription only access, and limiting appeal by banning flavours and attractive packaging. The full report is available online: Notes to Editors About the report The Future of Chronic Respiratory Diseases (CRDs) and Nicotine Consumption: Beyond Smoke and Mirrors report was developed in a two-phase approach. The first phase combined desk research and expert interviews to generate the evidence base, complemented with an AI model built by the CIFS team which included 4,000 peer-reviewed articles and policy documents. To ensure the integrity of the evidence base, studies linked to the tobacco industry were excluded. The second phase comprised two co-creation workshops that convened more than 20 tobacco-control specialists from Africa, Europe, the Middle East, North America, South America, and Southeast Asia. Participants were selected both for the relevance of their expertise and to ensure a diversity of viewpoints. In the first workshop, the experts identified critical uncertainties to structure the four future scenarios. In workshop two, participants revisited the four draft scenarios to explore early warning signs and tipping points suggesting that a particular trajectory is beginning to unfold, and the strategic trade-offs stakeholders may face. This report was commissioned by Sanofi and Regeneron. CIFS independently conducted the research, expert interviews, workshop facilitation, and the development of all scenarios and recommendations. While Sanofi and Regeneron provided financial support, CIFS maintained full editorial independence. Neither the Copenhagen Institute for Futures Studies nor Sanofi and Regeneron have any affiliation with the tobacco or nicotine industry. About the Copenhagen Institute for Futures Studies (CIFS) The Copenhagen Institute for Futures Studies is an independent, non-profit think tank established in 1969, on the initiative by former Danish Minister and OECD Secretary-General Professor Thorkil Kristensen. Our purpose is to help people and organisations imagine, work with, and shape their future. We do this by applying our unique approach to futures studies and foresight, combined with more than 50 years of global experience and contributions to the field, working with organisations across the public, private, academic, and civic sectors, as well as with the general public. Being independent of commercial and political interests enables an objective approach and allows for all profits to go exclusively to fund further research and non-profit initiatives. Logo - View original content to download multimedia: SOURCE Copenhagen Institute for Futures Studies (CIFS)
Yahoo
14 hours ago
- Yahoo
AIxMed and CorePlus Partner to Demonstrate a Digital Urine Cytology Workflow Solution
AIxMed and CorePlus team up to bring AI-driven quality control to improve bladder cancer diagnostics. SANTA CLARA, Calif., May 30, 2025 /PRNewswire/ -- AIxMed, innovators and providers of an AI-powered computational platform for cytology applications, and CorePlus have entered a Memorandum of Understanding to evaluate a Quality Control workflow solution for urine cytology. The partnership aims to demonstrate the integration of artificial intelligence into the urine cytology workflow, enhancing diagnostic consistency, efficiency, and scalability. AIxMed's experience in AI-based cytology software and analysis, combined with CorePlus' experience in integrating digital and AI solutions into their day-to-day pathology workflow will come together to provide an end-to-end solution for research-use only cytology analysis. "We are thrilled to collaborate with CorePlus in demonstrating how AIxURO can seamlessly integrate into their digital pathology workflow. This effort builds on the success of our previous studies and marks an important milestone toward modernizing cytology quality control (QC) through digital and AI tools," said Samuel Chen, CEO of AIxMed. "AIxURO offers significant time savings with consistent results. Integrating our scanner with real-time AI-based QC checks significantly improves efficiency and diagnostic accuracy. Precision cytology is no longer a vision—it's reality," said Mariano de Socarraz, Founder, and CEO of CorePlus. The scarcity of cytologists and the manual process involved in cell characterization necessitate the development of advanced tools to enhance workflow and offer both quantitative and qualitative insights. AI-driven computational tools have the potential to provide these valuable insights and enable the processing of a greater number of slides with the existing workforce. To learn more about these solutions or to request a demonstration, please visit About AIxMedFounded in 2018, AIxMed is creating a roadmap to transforming cancer diagnosis and monitoring through our smart computational cytology platform. This solution simplifies clinical workflows and richly strengthens the quality of healthcare by aiding critical decision support during clinical diagnosis and monitoring. To learn more visit About CorePlusCorePlus is a state-of-the-art precision pathology organization based in Puerto Rico, committed to diagnostic excellence through innovation and technology. With a patient-centered approach and quality-driven processes, CorePlus is at the forefront of adopting artificial intelligence algorithms as decision support tools for our pathologists offering unprecedented accuracy and efficiency. To learn more visit View original content to download multimedia: SOURCE AIxMed, Inc.
